|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
VANCOUVER, Canada--(BUSINESS WIRE)--July 10, 1996--Enzo Biochem (ASE:ENZ) of Famingdale, N.Y.
announced today that its scientists and collaborators have produced human immune cells that are completely and stably
resistant to multiple challenges of HIV.
This approach is targeted to provide the medical community with a powerful new weapon in the fight against AIDS.
The Company said that following completion of the preclinical studies, it plans to move ahead towards the development
of protocols for human clinical studies.
These findings were released today at the 11th International Conference on AIDS in a presentation by Norman Kelker,
Ph.D., Senior Vice President of Enzo and a participating scientist at the conference. The studies show that CD4+ cells,
that are normally sensitive to HIV-1 infection, are protected when treated with Enzo's antisense construct. Resistance
to HIV-1, which was shown to correlate with production of antisense RNA by the cells, could lead to restoring
immune competence in patients, even in the presence of challenge by HIV.
"We have now successfully demonstrated that we can create CD4+ cells that are resistant to HIV-1 and that maintain
their resistance to the virus over a prolonged period," said Dr. Kelker. "This is a very important step in moving
towards the development of an effective clinical product for HIV therapy. We believe that our antisense therapy alone,
or in combination with already established protocols, can become an effective and widely applied treatment for
Enzo's approach utilizes methods to overcome effects due to the variability and mutability of the virus and to localize
the antisense in the cell nucleus where its antiviral activity is most effective. The Company noted that, unlike currently
used treatments aimed at viral reverse transcriptase or protease, its antisense approach is designed not to require
According to the report, which presents results from a more than year-long study, Enzo's therapeutic approach is
aimed at inhibiting expression of HIV-1 genes by antisense RNA. The approach is gene specific and does not affect
cellular genes. Thus, the establishment of such antisense-producing immune cells in the patient could protect against
collapse of the immune system in AIDS patients. The therapy would be applied to immune cells removed from the
patient and altered ex vivo, that is, outside the body, by the introduction of antisense producing genes. Altered cells
reimplanted in the patient are expected to propagate HIV-resistant immune cells.
Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on
molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.
CONTACT: Barry Weiner, 212/856-0876
Steve Anreder, 212/421-4020
|© 2020 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|